Maxim Group downgraded VistaGen from Buy to Hold
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/17/2025 | $0.90 | Buy → Hold | Jefferies |
| 12/17/2025 | Buy → Hold | Maxim Group | |
| 12/17/2025 | Outperform → Mkt Perform | William Blair | |
| 12/17/2025 | $1.00 | Buy → Hold | Stifel |
| 12/7/2023 | $15.00 | Hold → Buy | Jefferies |
| 8/7/2023 | $30.00 | Hold → Buy | Maxim Group |
| 7/22/2022 | Outperform → Neutral | Robert W. Baird | |
| 7/22/2022 | Buy → Hold | Jefferies |
Jefferies downgraded VistaGen from Buy to Hold and set a new price target of $0.90
Maxim Group downgraded VistaGen from Buy to Hold
William Blair downgraded VistaGen from Outperform to Mkt Perform
4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
3 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
Vistagen, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Company will participate in the Jefferies 2026 Global Healthcare conference being held June 2-4, 2026, in New York City. The Company will host one-on-one meetings with institutional investors during the conference. Investors interested in scheduling a meeting with Vistagen are encouraged to contact their Jefferies representative. About Vistagen Vistagen (NASDAQ:VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-
Dr. Angelov brings extensive industry experience across multiple therapeutic areas Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Angel S. Angelov, MD, MBA, as Chief Medical Officer (CMO), effective May 18, 2026. "We are pleased to welcome Dr. Angelov to the Vistagen team," said President and Chief Executive Officer of Vistagen, Shawn Singh. "His two decades of leadership across clinical development and medical affairs, including roles at Karuna, Neurocrine, Novartis, and Teva, wil
Vistagen, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat at the RBC Capital Markets Global Healthcare conference on Wednesday, May 20, 2026, at 2:35 p.m. Eastern Time. The Company will also host one-on-one meetings during the conference. The live webcast link will be available in the Investors section of Vistagen's website, under the "Events" tab. A replay of the webcast will be archived on the Company's website following the presenta
8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
Dr. Angelov brings extensive industry experience across multiple therapeutic areas Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Angel S. Angelov, MD, MBA, as Chief Medical Officer (CMO), effective May 18, 2026. "We are pleased to welcome Dr. Angelov to the Vistagen team," said President and Chief Executive Officer of Vistagen, Shawn Singh. "His two decades of leadership across clinical development and medical affairs, including roles at Karuna, Neurocrine, Novartis, and Teva, wil
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po
Mr. Edick brings extensive industry experience across product development, commercial launch, and growth strategy Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Mr. Paul Edick to its Board of Directors ("Board"). Following the appointment of Mr. Edick, Vistagen's Board will be comprised of seven directors. Mr. Edick will serve on the Audit Committee and the Compensation Committee of the Board. "We are pleased to welcome Mr. Edick to our Board of Directors," said Maggie FitzPatrick,
PALISADE-4 Phase 3 Trial of fasedienol for acute treatment of Social Anxiety Disorder proceeding, with topline results from the randomized portion of the trial expected in the first half of 2026 Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 third quarter ended December 31, 2025, and provided a corporate update. "We have reviewed available data from PALISADE-3 and implemented moderate refinements, including retraining, site rationalization, and operational en
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, February 12, 2026, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2026 third quarter ended December 31, 2025, and provide a corporate update. The conference call is being webcast live, and a link can be found under "Events" in the Investors section of the Company's website. Please click on the webcast link and follow the prompts for registration and access at
PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder is Complete; Topline results expected by calendar year end Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 second quarter ended September 30, 2025, and provided a corporate update. "As we conclude the second quarter of our fiscal year, we are encouraged by our progress and remain confident in the path ahead," said Shawn Singh, President and Chief
SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)
SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)
SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)